The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.
 
Jeffrey A Bogart
Stock and Other Ownership Interests - Cardan Robotics; Verve Medical
 
Xiaofei F. Wang
No Relationships to Disclose
 
Gregory A. Masters
No Relationships to Disclose
 
Junheng Gao
No Relationships to Disclose
 
Ritsuko Komaki
No Relationships to Disclose
 
Charles S. Kuzma
No Relationships to Disclose
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Lilly; Sanofi/Aventis; Spectrum Pharmaceuticals; Syntha Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bayer; GlaxoSmithKline; Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations
 
William J. Petty
Consulting or Advisory Role - Jazz Pharmaceuticals
Research Funding - Abbvie (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Dava Oncology
 
Laurie E. Gaspar
Employment - Banner MD Anderson Colorado
Speakers' Bureau - Cancer Experts Now
Other Relationship - NCI
 
Saiama Naheed Waqar
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Hengrui Therapeutics (Inst); Ignyta (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Stem CentRx (Inst); Synermore biologics (Inst); Vertex (Inst); Xcovery (Inst)
 
Tom Stinchcombe
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; EMD Serono; Foundation Medicine; Genentech/Roche; Janssen Oncology; Lilly; Medtronic; Novartis; Pfizer; Puma Biotechnology; Regeneron; Takeda
Research Funding - Advaxis (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Genentech/Roche (Inst); Regeneron (Inst); Takeda (Inst)
 
Jeffrey D. Bradley
Honoraria - AstraZeneca/MedImmune; Mevion Medical Systems
Consulting or Advisory Role - Genentech; Varian Medical Systems
 
Everett E. Vokes
Stock and Other Ownership Interests - Coordination Pharmaceuticals
Honoraria - Abbvie; Ascendis Pharma (I); AstraZeneca; BeiGene; BioNTech; EMD Serono; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Radius Health (I); Takeda (I)
Consulting or Advisory Role - Abbvie; Ascendis Pharma (I); AstraZeneca; BeiGene; BioNTech; EMD Serono; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Radius Health (I); Takeda (I)
Research Funding - Abbvie; Bristol-Myers Squibb; Celgene; Lilly (Inst); Novartis
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; BeiGene; BioNTech; EMD Serono; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis